Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Collyar: What's In It for Patients?

Opening Session Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




May
01
Today In Oncology
Belzutifan–Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
Acupuncture for Nocturia in Survivors of Prostate Cancer
Metabolic Tumor Volume Predicts CAR T-Cell Therapy Response in LBCL
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo